Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT04407988 Recruiting - Clinical trials for Metastatic Breast Cancer

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

Start date: November 6, 2019
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, multi-center clinical study of pyrotinib in combination With letrozole in patients With HER2-Positive, ER-Positive metastatic breast cancer. Our aim was to explore the efficacy and safety of pyrotinib combined with letrozole in patients with HER2-positive, ER-positive metastatic breast cancer.

NCT ID: NCT04406779 Completed - Breast Cancer Clinical Trials

The Frequency of Thyroid Diseases in Women With Breast Cancer

Start date: March 1, 2016
Phase:
Study type: Observational

Breast cancer and thyroid disorders are important health challenges commonly encountered in women. The relationship between both conditions still remains unknown. In this study, the frequency of thyroid diseases was investigated in breast cancer patients

NCT ID: NCT04405505 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Start date: June 1, 2020
Phase: Phase 3
Study type: Interventional

This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus paclitaxel for injection (albumin bound) in subjects with advanced triple negative breast cancer.

NCT ID: NCT04403984 Active, not recruiting - Breast Cancer Clinical Trials

Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes

Start date: April 24, 2013
Phase:
Study type: Observational

This is a translational study in patients with operated early breast cancer of Luminal A or Luminal B sub types.The Hellenic Cooperative Oncology Group (HeCOG) has designed an observational biomarker-driven study in patients with Luminal A or Luminal B breast cancer, with the aim to collect valuable biological material from these patients and investigate biomarkers with potential prognostic value.

NCT ID: NCT04403529 Recruiting - Clinical trials for Triple Negative Breast Cancer

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Start date: May 25, 2020
Phase: Phase 3
Study type: Interventional

This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.

NCT ID: NCT04400695 Recruiting - Breast Cancer Clinical Trials

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Start date: September 29, 2020
Phase: Phase 3
Study type: Interventional

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

NCT ID: NCT04400552 Completed - Cancer of Breast Clinical Trials

Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients

Start date: December 26, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effectiveness of perioperative oral nutrition supplementation (ONS) on nutritional status in malnourished cancer patients undergoing elective surgery. The hypothesis is pre-operative ONS feeding in malnourished surgical cancer patients is effective on improving nutritional status. An extended period of 3 months post-operative ONS feeding is effective on improving nutritional status as compared to ONS feeding post-operatively during hospital stay only. Perioperative feeding is effective on improving secondary outcomes such as sleep quality, post-operative complications and length of hospital stay.

NCT ID: NCT04398914 Active, not recruiting - Clinical trials for Breast Cancer Invasive

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Start date: May 30, 2020
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, pertuzumab and nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced HER2-positive breast cancer.

NCT ID: NCT04398108 Completed - Clinical trials for HER2 Positive Metastatic Breast Cancer

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Start date: August 25, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, Single-arm, Phase I clinical study to evaluate the pharmacokinetics, tolerability and safety of margetuximab plus chemotherapy in Chinese patients with advanced HER2+ breast cancer who have received standard anti-HER2 directed therapy in the metastatic setting (mandatory including trastuzumab). The primary endpoint of this study is PK parameters of margetuximab.

NCT ID: NCT04397185 Recruiting - Clinical trials for Breast Cancer Female

Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

Start date: December 23, 2020
Phase: N/A
Study type: Interventional

This prospective, multicenter, 1:1 randomized, controlled trial is designed to evaluate the safety and effectiveness of the Breast Cancer Locator (BCL) in subjects with non-palpable invasive breast cancer or ductal carcinoma in situ (DCIS). Subjects will be randomized to breast conserving surgery (BCS) utilizing either the BCL or wire localization (WL) to guide surgery.